knowledge -WSS

knowledge

author：hotspot 2025-09-30 18:54:50 - browse：31171

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Readout Newsletter: Geron, Novo Nordisk, WuXi updates

focus

WSS

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Undocumented workers face uncertainty as immigration law takes effect in Florida

Canadians with cystic fibrosis outlive Americans by a decade

Gene editing the human germline: What are the risks?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Intermittent fasting comes with a heart risk? Not so fast

Wikipedia

knowledge

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Prescription digital therapeutics are key to pharma’s future

At least 13 dead in Texas as scorching temps continue

Intermittent fasting comes with a heart risk? Not so fast

Trump demands the U.S. pay no more for drugs than other countries … again

Dexcom's push to bring CGM to type 2 diabetes patients

The cancer drug shortage isn’t new — and neither are the solutions

Prescription digital therapeutics are key to pharma’s future

State Dept. review finds Biden bears some blame for Afghanistan failures

What affirmative action's end means to a medical student

focus

Fatty liver disease was alleviated by Lilly’s ‘triple

Virtual Event: March of the Biosimilars

Asbestos, a deadly carcinogen, banned by EPA

Methadone treatment changes are coming. Do they go far enough?

A letter from the executive editor: The 2023 STATUS List

Neuroscience’s long legacy of racism

knowledge

knowledge

focus

explore